Zenas BioPharma, Inc.
NASDAQ: ZBIO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leon Oliver Moulder Jr.
- Employees
- 130
- Headquarters
- Waltham, United States
- IPO year
- 2024
- Market cap
- $973.2M
- Website
- https://zenasbio.com
Loading ZBIO…
Loading profile data…Frequently asked questions about ZBIO
What does Zenas BioPharma, Inc. (ZBIO) do?
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-r...
Where does ZBIO trade?
Zenas BioPharma, Inc. (ZBIO) trades on the NASDAQ Global Select.
What sector is ZBIO in?
Zenas BioPharma, Inc. (ZBIO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Zenas BioPharma, Inc.?
Leon Oliver Moulder Jr. is the chief executive officer of Zenas BioPharma, Inc. (ZBIO).
Where is Zenas BioPharma, Inc. headquartered?
Zenas BioPharma, Inc. is headquartered in United States.
Does ZBIO pay a dividend?
Zenas BioPharma, Inc. (ZBIO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ZBIO go public?
Zenas BioPharma, Inc. (ZBIO) completed its initial public offering in 2024.